[go: up one dir, main page]

EP3962488A4 - Procédé de traitement de troubles mentaux, comportementaux et cognitifs - Google Patents

Procédé de traitement de troubles mentaux, comportementaux et cognitifs Download PDF

Info

Publication number
EP3962488A4
EP3962488A4 EP19927207.1A EP19927207A EP3962488A4 EP 3962488 A4 EP3962488 A4 EP 3962488A4 EP 19927207 A EP19927207 A EP 19927207A EP 3962488 A4 EP3962488 A4 EP 3962488A4
Authority
EP
European Patent Office
Prior art keywords
behavioral
cognitive disorders
treating mental
mental
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19927207.1A
Other languages
German (de)
English (en)
Other versions
EP3962488A1 (fr
Inventor
Jianmin Wang
Geping Cui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LA PharmaTech Inc
Original Assignee
LA PharmaTech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LA PharmaTech Inc filed Critical LA PharmaTech Inc
Publication of EP3962488A1 publication Critical patent/EP3962488A1/fr
Publication of EP3962488A4 publication Critical patent/EP3962488A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP19927207.1A 2019-04-30 2019-04-30 Procédé de traitement de troubles mentaux, comportementaux et cognitifs Pending EP3962488A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/029885 WO2020222799A1 (fr) 2019-04-30 2019-04-30 Procédé de traitement de troubles mentaux, comportementaux et cognitifs

Publications (2)

Publication Number Publication Date
EP3962488A1 EP3962488A1 (fr) 2022-03-09
EP3962488A4 true EP3962488A4 (fr) 2022-12-14

Family

ID=73029129

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19927207.1A Pending EP3962488A4 (fr) 2019-04-30 2019-04-30 Procédé de traitement de troubles mentaux, comportementaux et cognitifs

Country Status (6)

Country Link
EP (1) EP3962488A4 (fr)
JP (1) JP2022536017A (fr)
CN (1) CN113924098A (fr)
AU (1) AU2019443520A1 (fr)
CA (1) CA3137393A1 (fr)
WO (1) WO2020222799A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11318144B2 (en) 2019-04-12 2022-05-03 LA PharmaTech Inc. Compositions and methods for treating Alzheimer's disease and Parkinson's disease
US10966989B2 (en) 2019-04-12 2021-04-06 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
US11389458B2 (en) 2019-04-12 2022-07-19 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating parkinson's and huntington's disease
US10639314B1 (en) 2019-04-30 2020-05-05 LA PharmaTech Inc. Method of treating Alzheimer's disease
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US11351179B1 (en) 2021-08-05 2022-06-07 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of psychiatric disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020209872A1 (fr) * 2019-04-12 2020-10-15 La Pharma Tech Inc. Compositions pharmaceutiques et méthodes de traitement de troubles mentaux, comportementaux et cognitifs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849621B2 (en) * 2001-03-13 2005-02-01 Schering Corporation Piperidine compounds
BR0211810A (pt) * 2001-08-09 2004-08-24 Ono Pharmaceutical Co Derivados ácido carboxìlico e agente farmacêutico compreendendo os mesmos como ingrediente ativo
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
NZ535764A (en) * 2002-04-18 2007-10-26 Schering Corp 1-(4-piperidinyl) benzimidazolones as histamine H3 antagonists
GB0224084D0 (en) * 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020209872A1 (fr) * 2019-04-12 2020-10-15 La Pharma Tech Inc. Compositions pharmaceutiques et méthodes de traitement de troubles mentaux, comportementaux et cognitifs

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AIKO HATAKEYAMA ET AL: "AZELASTINE HYDROCHLORIDE ON BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS AND ACTIVITIES OF DAILY LIVING IN DEMENTIA PATIENTS", GERIATR. GERONTOL. INT,, vol. 8, 1 January 2008 (2008-01-01), pages 59 - 61, XP002798078 *
FRISCH C ET AL: "The histamine H"1-antagonist chlorpheniramine facilitates learning in aged rats", NEUROSCIENCE LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 229, no. 2, 27 June 1997 (1997-06-27), pages 89 - 92, XP027335978, ISSN: 0304-3940, [retrieved on 19970627] *
JOANNA GIRARD ET AL: "Azelastine protects against CA1 traumatic neuronal injury in the hippocampal slice", EUROPEAN JOUMAL OF PHARMACOLOGY, vol. 300, 1 January 1996 (1996-01-01), pages 43 - 49, XP055682773, DOI: 10.1016/0014-2999(95)00804-7 *
See also references of WO2020222799A1 *

Also Published As

Publication number Publication date
WO2020222799A1 (fr) 2020-11-05
CN113924098A (zh) 2022-01-11
CA3137393A1 (fr) 2020-11-05
AU2019443520A1 (en) 2021-12-23
JP2022536017A (ja) 2022-08-12
EP3962488A1 (fr) 2022-03-09

Similar Documents

Publication Publication Date Title
EP3962488A4 (fr) Procédé de traitement de troubles mentaux, comportementaux et cognitifs
EP4010072A4 (fr) Traitement de troubles du système nerveux central
EP3746135A4 (fr) Procédés et composés pour traiter des troubles
EP3973586A4 (fr) Nouvelles compositions pharmaceutiques et méthodes de traitement de troubles mentaux, comportementaux et cognitifs
EP4045037A4 (fr) Hétéroaryl-biphénylamines pour le traitement de maladies pd-l1
EP3806957A4 (fr) Procédés de diagnostic, de surveillance et de traitement de maladies et de troubles neurologiques
EP3681477A4 (fr) Méthode et composition améliorée pour le traitement d'états pathologiques, de maladies ou de troubles sensibles aux triterpènes
EP3969456A4 (fr) Procédés de traitement d'un trouble médié par mk2
EP4037684A4 (fr) Traitements cognitifs médicinaux
EP3990457A4 (fr) Composés pour le traitement de troubles oculaires
SG11202110659SA (en) Method for treating ocular diseases
EP4069239A4 (fr) Traitement de troubles cognitifs à l'aide de trapidil
EP4058063A4 (fr) Méthodes de traitement de maladies
HK40073332A (en) Methods for the treatment of epilepsy
HK40066606A (en) Azepino-indoles and other heterocycles for treating brain disorders
HK40109408A (zh) 一种环状rna、组合物和治疗疾病的方法
HK40066859A (en) Method and uses of diagnosing and recommending treatment for a psychotic disorder
AU2021903373A0 (en) Methods for treating disorders
AU2019904679A0 (en) A method of treatment
AU2019904600A0 (en) A method of treatment
EP4013227A4 (fr) Procédé de traitement de cultures
HK40053357A (en) Method for the treatment of mucopolysaccharidosis type i
HK40086640A (en) Method for the treatment nlrp3-associated diseases
AU2018900160A0 (en) A method of treating or preventing cancer or hyperproliferative disorders
HK40076432A (en) Compounds and methods for treating oxalate-related diseases

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211129

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20221110

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/16 20060101ALI20221104BHEP

Ipc: A61P 25/28 20060101ALI20221104BHEP

Ipc: A61K 31/55 20060101AFI20221104BHEP